Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 44896, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration.

For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692638/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Tuesday-March-15-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.01
+2.06 (0.95%)
AAPL  259.93
+1.48 (0.57%)
AMD  233.43
+3.20 (1.39%)
BAC  51.66
+0.55 (1.09%)
GOOG  254.86
+2.33 (0.92%)
META  736.42
+3.01 (0.41%)
MSFT  522.22
+1.68 (0.32%)
NVDA  182.04
+1.76 (0.98%)
ORCL  280.83
+8.17 (3.00%)
TSLA  445.81
+6.84 (1.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.